회사 개요
CNS Pharmaceuticals, Inc. (CNSP) operates as a clinical pharmaceutical entity dedicated to the development of anti-cancer drug candidates specifically targeting brain and central nervous system tumors. The company functions within the Healthcare sector and the Biotechnology industry, a classification that signifies its reliance on research and development rather than traditional manufacturing or sales. CNSP currently maintains a market capitalization of $1.73M, while its annual revenue is not disclosed in the provided financial data, and the employee count is listed as N/A. These valuation and scale metrics indicate that the company is a small-cap biotechnology firm with a limited market presence, suggesting its primary value proposition lies in its pipeline assets rather than established commercial cash flows. The absence of reported revenue and employee figures further underscores the early-stage nature of the business, where capital allocation is heavily weighted toward advancing clinical trials for candidates such as TPI 287 and Berubicin.
재무 건전성
The company reports a Net Income of $-15,850,564 and an EBITDA of $-15,982,641, while Revenue figures are not available, a common characteristic for pre-commercial biotechnology firms. The substantial gap between the reported Net Income and EBITDA reveals a significant impact from non-operating expenses or interest costs, although the lack of revenue data prevents a detailed gross margin analysis. Free Cash Flow stands at $-6,958,225, indicating that the company is burning cash to fund its operations and clinical development programs, which limits immediate financial flexibility but is typical for this stage of growth. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are 0.0%, reflecting the current inability to generate commercial profit from sales or operations. The balance sheet shows Cash of $7.20M against Debt of $328,571, resulting in a Debt to Equity ratio of 7.26, which suggests a highly leveraged position relative to equity, though the cash buffer provides a safety net against the debt obligation. The Current Ratio is 1.98, indicating that the company possesses sufficient current assets to cover its short-term liabilities, thereby demonstrating adequate short-term liquidity. Return on Equity is -296.3% and Return on Assets is -115.3%, metrics that reveal the company is currently destroying value per unit of capital invested due to heavy investment in clinical development without corresponding earnings.
밸류에이션 평가
CNSP does not have a Trailing P/E Ratio available due to negative earnings, while the Forward P/E is listed at -5.46, implying that future earnings projections are negative or the calculation is based on non-GAAP adjustments that result in a negative multiple. The Price to Book ratio is 0.12, which indicates that the market values the company at a fraction of its book value, suggesting significant market skepticism or a valuation based entirely on the potential of its clinical pipeline rather than tangible assets. The Price to Sales ratio is N/A, and the EV/EBITDA is 0.32, suggesting a valuation model that attempts to account for enterprise value despite the lack of positive earnings or sales data. The stock has a 52-Week High of $34.80 and a 52-Week Low of $2.06, meaning the current trading price sits significantly closer to the bottom of the range than the top, reflecting a period of high volatility and price compression. The Beta is 0.49, which indicates that the stock's price volatility is less than half that of the broader market, presenting a lower risk profile in terms of price movement relative to large-cap equities.
Growth & Income
Revenue Growth and Earnings Growth rates are both N/A, as the company has not yet achieved the scale to report year-over-year growth metrics in its financial statements. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all available capital to reinvest into its drug development pipeline rather than distributing income to shareholders. The lack of dividend payouts combined with negative earnings growth implies that the company is in a capital-intensive growth phase where profitability is sacrificed for the advancement of clinical candidates. The overall growth and income profile is characterized by a lack of current financial returns, with the entire business model dependent on the successful progression of its anti-cancer drug candidates through Phase 2 clinical trials to eventually generate commercial revenue and positive cash flow.